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T ype 1 diabetes mellitus (T1D) is caused by severe insulin deficiency that typically results from an 
autoimmune destruction of pancreatic beta cells [1].  
Fulminant type 1 diabetes mellitus (FT1D) is a subtype 
of T1D,  characterized by the abrupt onset of insu-
lin-deficient severe hyperglycemia,  diabetic ketoacido-
sis (DKA),  high serum pancreatic enzyme levels,  and 
no diabetes-related autoantibodies [2].
Here we report the case of a patient infected with 
human immunodeficiency virus (HIV) who subse-
quently developed FT1D.
Case Report
A previously healthy 40-year-old Japanese male 
(173.5 cm,  56.8 kg) was admitted to our emergency 
department with a 2-month history of dysphagia,  
30-kg weight loss,  fever,  dyspnea,  and occasional 
cough with purulent sputum.  He was febrile (100.2°F;  
37.9°C),  had an oxygen saturation of 86% while not 
receiving oxygen,  a pulse rate of 128 beats per min,  a 
respiratory rate of 30 breaths per min,  and blood pres-
sure values of 138/97 mmHg.  He had an oropharyngeal 
cyst and inspiratory crackles in both hemithoraces.  
Laboratory findings were as follows: WBC count,  
8,290 cells/mm3; hematocrit,  34.2% ; platelets,  
268,000/mm3; creatinine,  0.53 mg/dL; alanine ami-
notransferase,  26 U/mL; aspartate aminotransferase,  
47 U/mL; total bilirubin,  0.5 mg/dL; β-D glucans,  
207.0 pg/mL.  The CD4 count was 28 cells/μL.  
Computed tomography (CT) revealed marked patchy to 
almost diffuse ground-glass opacity (Fig. 1).  HIV anti-
bodies (Western blot) and pp65 cytomegalovirus 
(CMV) antigenemia test (C7-HRP) were positive 
(15 infected cells/50,000 leucocytes).
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We suspected pneumocystis pneumonia (PCP) and 
CMV pneumonia,  and we diagnosed the patient as 
having acquired immunodeficiency syndrome (AIDS).  
The mycobacterial culture examination and polymerase 
chain reaction for the detection of mycobacterium 
tuberculosis were negative.  Pentamidine (240 mg×1/day 
i.v.),  methylprednisolone (mPSL) (500 mg × 2/day i.v.),  
and ganciclovir (250 mg × 2/day i.v.) were initiated 
(Fig. 2).  Antiretroviral therapy was not performed at 
that time.  Thereafter,  the patient’s respiratory status 
improved (oxygen saturation was 100% while receiving 
2 L of oxygen through a nasal cannula),  with a good 
level of consciousness.
On hospital day 9,  chest CT revealed that the patchy 
to almost diffuse ground-glass opacity had faded some-
what overall,  and the infiltrative shadow had also 
decreased.  β-D glucans decreased as well,  to 127.8 pg/mL.  
CMV antigenemia became negative 20 days after the 
initial positive test.  We decreased the ganciclovir to 
once per day (250 mg × 1/day i.v.) 25 days after its initi-
ation.  The patient’s blood glucose was 86 mg/dL,  and 
the onset of diabetes mellitus (DM) was not confirmed 
at that time.  However,  on hospital day 13,  the patchy to 
almost diffuse ground-glass opacity and the infiltrative 
shadow had become more prominent,  and thus antiret-
roviral therapy was not administered.  In addition,  only 
1 week had passed since the previous CD4 + cell count;  
as measurements were not taken at this point in time,  
an estimate of CD4+  cells is unavailable.  On hospital 
day 28,  CT revealed that the infiltrative shadow had 
worsened relative to the previous evaluation.
The patient became comatose and experienced car-
diopulmonary arrest on hospital day 41.  He was then 
transferred to our intensive care unit (ICU) after tra-
cheal intubation and resuscitation and was found to be 
markedly dehydrated with systolic blood pressure 
108 mmHg,  diastolic blood pressure 49 mmHg,  heart 
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CRP WBC Plt Amylase
Ganciclovir 500mg/day 250mg
mPSL
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???.  ?　 Time course of the patientʼs laboratory data,  antibiotic treatment,  and steroid administration.  mPSL: methylprednisolone.
???.  ?　 CT revealed marked patchy-to-almost diﬀuse ground-
glass opacity.
rate 115 beats/min,  and respiratory rate 28 breaths per 
min.  His oxygen saturation was 100% while receiving 
100% oxygen with an Ambu bag (10 L oxygen).  After 
ICU admission,  the patient was connected to a ventila-
tor using the CPAP + PS mode (FiO2 1.0,  PEEP3,  PS 
5).  At that point,  a blood gas analysis revealed a PaO2 
of 512 mmHg and pCO2 of 31 mmHg,  and his body 
temperature was 96.4°F (35.8°C).  Laboratory findings 
were as follows (Table 1): WBC count,  3,000 cells/mm3;  
hematocrit,  27.6%; platelets,  61,000/mm3; creatinine,  
3.60 mg/dL; alanine aminotransferase,  33 U/mL;  
aspartate aminotransferase,  29 U/mL; total bilirubin,  
0.5 mg/dL.  The laboratory data revealed severe hyper-
glycemic ketoacidosis (plasma glucose,  39.5 mmol/L 
[711.0 mg/dL]; 3-hydroxyburytic acid,  663 μmol/L 
[6.9 mg/dL] ;  arterial pH,  6.89 ;  bicarbonate,  
10.4 mmol/L),  glycosylated hemoglobin (7.6% of total 
hemoglobin),  and glycated albumin (30.0% of total 
albumin).
Our analysis of sera obtained at the patient’s ICU 
admission revealed a rapid loss of C peptide to 0.03 ng/
mL,  from 5.88 ng/mL measured 19 days before the ICU 
admission.  The pancreatic enzyme levels were elevated 
(serum amylase,  151 U/L).  Glutamic acid decarboxy-
lase antibodies were negative.  A glucagon load test was 
not performed at that time.  The patient was diagnosed 
with FT1D.  His hyperglycemia and metabolic acidosis 
were treated with the standard treatment for DKA by 
measuring blood glucose levels at 30-min intervals,  an 
infusion of 3,200 mL of normal saline and 5,200 mL of 
Ringer’s acetate per day,  and continuous insulin injec-
tions (3-5 units/h),  which were gradually decreased.
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????? ?　 Laboratory ﬁndings at the patientʼs hospital admission and at the onset of fulminant type 1 diabetes
Variable On admission After the onset of FT1D
Complete blood count
White blood cell count (/µL) 8,290.00 3,000.00
Neutrophils (%) 76.50 97.00
Lymphocytes (%) 17.00 1.00
Monocytes (%) 4.80 2.00
Eosinophils (%) 0.40 0.00
Basophils (%) 0.40 0.00
Red blood cells (×104/µL) 370.00 296.00
Hemoglobin (g/dL) 11.60 8.90
Platelet count (×104/µL) 26.80 61.00
Biochemistry
Blood urea nitrogen (mg/dL) 13.00 126.00
Creatinine (mg/dL) 0.53 3.60
Amylase (IU/L) 97.00 151.00
C-reactive protein (mg/dL) 1.15 0.03
Na (mEq/L) 139.00 153.00
K (mEq/L) 3.60 4.50
Cl (mEq/L) 98.00 101.00
Glucose (mg/dL) 120.00 711.00




Ketone body - +
Occult blood - -
Diabetes-related tests
Serum CPR (ng/mL) 5.88 (23rd day) 0.03
Anti-GAD antibody <5.0 <5.0
CPR: C-peptide Immunoreactivity,  GAD: Glutamic Acid Decarboxylase
When the speed of the insulin infusion was reduced 
to 0.5 units/h or halted,  the patient developed hypogly-
cemia (29 mg/dL or 39 mg/dL,  respectively) and hypo-
tension (systolic blood pressure 60-70 mmHg when 
dopamine was administered at 12 mg/h) at 17 or 21 h 
after ICU admission,  respectively (Fig. 3).  Pro-
calcitonin (PCT) was 10.0 ng/mL and Klebsiella pneu-
moniae and methicillin-susceptible Staphylococcus 
aureus were isolated from 2 blood sample cultures 
(arterial blood) collected 22 h after the patient’s ICU 
admission.  We diagnosed adrenal insufficiency accom-
panied by septic shock,  and hydrocortisone (100 mg× 4 
per day) was started.  Although standard therapy was 
provided for septic shock,  the patient died of multiple 
organ failure 29 h after his ICU admission.  As dis-
cussed above,  given his critical condition and sudden 
disease progression,  we were unable to perform CT 
scans during the time period from before admission to 
the ICU to after his discharge from the ICU.  Moreover,  
we did not measure the amount of CD4 + cells.  An 
autopsy was not performed,  as the family’s consent 
could not be obtained.
Consent for publication: Written informed con-
sent was not obtained from the patient for the publica-
tion of this case report and accompanying images,  due 
to his sudden death from sepsis.  As he wished not to 
inform his family or relatives that he was infected with 
HIV,  we could not obtain written informed consent 
from his family or relatives either.  The publication of 
this case report was approved by the Ethics Committee 
of Osaka Medical College (Osaka,  Japan).
Discussion
Here we report the case of a patient with HIV infec-
tion who developed FT1D.  We discuss the following 3 
aspects: (1) the association between HIV/AIDS and 
FT1D,  (2) FT1D onset despite negative CMV antigene-
mia,  and (3) the cause of severe hypoglycemia during 
the course of FT1D.  To the best of our knowledge,  no 
previous studies have reported on HIV and/or FT1D as 
comorbidities.
What underlies the onset of FT1D despite negative 
CMV antigenemia? We propose 3 hypotheses.  First,  
several types of viruses (including CMV) are known to 
be involved in the development of FT1D [3].  Potential 
mechanisms for the role of human CMV in T1D may 
involve “(1) molecular mimicry induced by T-cell 
cross-reactivity between human cytomegalovirus and 
GAD65 in pancreatic islet β-cells; (2) the persistence of 
HCMV specific CD4 + T-cells or a bystander activi-
ty; and (3) persistent infection in β-cells” [3 , 4].  FT1D 
may involve a similar type of pathogenesis.  Kotani et al.  
[5] investigated the T-lymphocyte response against pan-
creatic beta cell antigens in F1TD,  wherein a peripheral 
immune reaction was observed in 69.2% of F1TD 
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???.  ?　 Time course of the patientʼs blood pressure,  laboratory data,  and continuous insulin injections after ICU admission.
patients,  indicating that autoreactive T cells might con-
tribute to FT1D development.  Although our patient’s 
CMV antigenemia was lost and his FT1D was unaf-
fected at that time,  the downstream effects initiated by 
CMV infection may have proceeded gradually until 
FT1D onset.
Second,  Kano et al.  [6] reported that several types 
of herpesviruses can be reactivated in a severe drug-in-
duced multiorgan reaction in the same sequential order 
as that observed in graft-versus-host disease.  Although 
our patient’s CMV antigenemia was negative before his 
FT1D onset,  other viruses may have been reactivated in 
the patient,  leading to the development of FT1D.
Third,  the toxicity of pentamidine to beta cells in 
islets may be involved [7 , 8].  Bouchard et al.  [7] 
reported that patients treated with pentamidine for PCP 
exhibited severe fasting hypoglycemia during the treat-
ment and had inappropriately high insulin levels in the 
post-absorptive state.  In contrast,  our patient did not 
exhibit severe fasting hypoglycemia from the time of the 
initiation of pentamidine administration to the onset of 
his FT1D (average glucose was 102.5 mg/dL during this 
period),  making it unlikely that pentamidine was the 
cause of our patient’s FT1D.
What caused the patient’s severe hypoglycemia 
during the course of FT1D? This could be explained by 
adrenal insufficiency accompanied by septic shock.  As 
reported by Annane et al.,  “Severe sepsis may be asso-
ciated with relative adrenal insufficiency or systemic 
inflammation-induced glucocorticoid receptor resis-
tance” [9].  Our patient was in septic shock when he 
experienced severe hypoglycemia,  since his procalci-
tonin was pretty high (10.0 ng/mL),  a blood sample 
culture was positive,  and he had severe hypotension.  
On the other hand,  tuberculosis of the adrenals might 
have been negative,  since the results of a mycobacterial 
culture examination and polymerase chain reaction for 
the detection of mycobacterium tuberculosis were neg-
ative.
CT scans on the patient’s hospital day 28 showed no 
adrenal hemorrhage,  and no evidence for Waterhouse-
Friderichsen syndrome was observed.  Moreover,  CT 
scans were not taken before the patient’s admission to or 
after his discharge from the ICU.  Waterhouse-
Friderichsen syndrome is typically caused by Neisseria 
meningitidis,  but it has also been reported to be caused 
by Streptococcus pneumoniae,  Neisseria gonorrhoeae,  
Pseudomonas aeruginosa,  Escherichia coli,  Haemophilus 
influenzae,  and Staphylococcus aureus [10].  In the pres-
ent case,  Klebsiella pneumoniae and methicillin-suscep-
tible Staphylococcus aureus were isolated from 2 blood 
sample cultures (arterial blood) collected 22 h after his 
ICU admission.  For cases that involve hypoglycemia 
and shock as in the present case,  a differential diagnosis 
of Waterhouse-Friderichsen syndrome should be con-
sidered.  Severe hypoglycemia during the course of 
FT1D is both very rare and a highly significant finding 
in this respect.  However,  we regret that the patient’s 
cortisol and ACTH levels were not measured at the time 
of FT1D onset.
In conclusion,  we report the case of a patient with 
FT1D and HIV infection who lost CMV antigenemia 
prior to FT1D onset and exhibited severe hypoglycemia 
during the course of FT1D.
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